抗肝癌Ⅰ号方改善早、中期原发性肝细胞癌患者生活质量的临床研究
|
摘要
目的探究抗肝癌Ⅰ号方对早、中期原发性肝细胞癌患者生活质量改善情况。方法纳入早、中期原发性肝细胞癌患者36例,口服抗肝癌Ⅰ号方,连续治疗6个月。于治疗前、治疗3个月和治疗6个月时观察患者生活质量、中医证候改善情况。结果①生活质量评分比较:肝癌患者在口服抗肝癌Ⅰ号方治疗期间,躯体功能、角色功能、情绪功能、认知功能、社会功能、总健康状况、疲倦、疼痛、气促、失眠、食欲丧失、便秘、腹泻评分持续改善,差异具有统计学意义(P <0. 05)。②中医证候评分比较:中医证候量化总积分在治疗期间持续降低(P <0. 05)。肝癌患者胁痛、胸闷善太息、食少、脘闷、情绪抑郁、嗳气、腹胀、面色晦暗、大便干结、口黏不欲饮、心烦、易怒、口苦、口干咽燥、溲赤、烦渴、耳鸣、膝软、失眠症状积分在治疗期间持续降低(P <0. 05)。结论初步观察到抗肝癌Ⅰ号方能够提高早、中期原发性肝细胞癌患者生活质量、缓解临床症状,且长期服药效果较短期服药效果好。
Objective To observe the improvements of life quality of the patients with the early and middle stages hepatocellular carcinoma after treatment by using No. 1 Anti Liver Cancer Prescription. Methods Thirty-six patients with early and middle stages hepatocellular carcinoma were included in this study. The patients took No. 1 Anti Liver Cancer Prescription orally for 6 months continuously. The medical indicators including the quality of life and traditional Chinese medicine( TCM) syndromes were measured and recorded before the treatment,at the 3 nd month of the treatment and at the end of the treatment. Results ① Comparison of quality of life scores: The scores of physical function,role function,emotional function,cognitive function,social function,general health status,fatigue,pain,shortness of breath,insomnia,loss of appetite,constipation and diarrhea were improved continuously. The difference was statistically significant( P < 0. 05). ② Comparison of TCM syndromes scores: Total score of TCM syndromes was decreased during the treatment period( P < 0. 05). The syndrome scores of hypochondriac pain,chest tightness and easy to sigh,loss of food-intake,stomach bilges,depressed,belching,abdominal distension,gloomy complexion,dry stool,mouth stick without desire to drink,upset,irritability,bitter taste,mouth and pharyngeal dry,yellow urine,polydipsia,tinnitus,knee weakness,and insomnia were decreased during the treatment period( P < 0. 05). Conclusion Preliminary observation,No. 1 Anti Liver Cancer Prescription was able to improve the quality of life of patients with early and middle stages hepatocellular carcinoma. It can also alleviate clinical symptoms. The meditation effect of long-term treatment is better than that of short-term treatment.
Objective To observe the improvements of life quality of the patients with the early and middle stages hepatocellular carcinoma after treatment by using No. 1 Anti Liver Cancer Prescription. Methods Thirty-six patients with early and middle stages hepatocellular carcinoma were included in this study. The patients took No. 1 Anti Liver Cancer Prescription orally for 6 months continuously. The medical indicators including the quality of life and traditional Chinese medicine( TCM) syndromes were measured and recorded before the treatment,at the 3 nd month of the treatment and at the end of the treatment. Results ① Comparison of quality of life scores: The scores of physical function,role function,emotional function,cognitive function,social function,general health status,fatigue,pain,shortness of breath,insomnia,loss of appetite,constipation and diarrhea were improved continuously. The difference was statistically significant( P < 0. 05). ② Comparison of TCM syndromes scores: Total score of TCM syndromes was decreased during the treatment period( P < 0. 05). The syndrome scores of hypochondriac pain,chest tightness and easy to sigh,loss of food-intake,stomach bilges,depressed,belching,abdominal distension,gloomy complexion,dry stool,mouth stick without desire to drink,upset,irritability,bitter taste,mouth and pharyngeal dry,yellow urine,polydipsia,tinnitus,knee weakness,and insomnia were decreased during the treatment period( P < 0. 05). Conclusion Preliminary observation,No. 1 Anti Liver Cancer Prescription was able to improve the quality of life of patients with early and middle stages hepatocellular carcinoma. It can also alleviate clinical symptoms. The meditation effect of long-term treatment is better than that of short-term treatment.
引文
[1]陈建国.中国肝癌发病趋势和一级预防[J].临床肝胆病杂志,2012,28(4):256-260.
[2]中华人民共和国卫生部.原发性肝癌诊疗规范2011年版[J].临床肿瘤学杂志,2011,16(10):929-946.
[3]汤钊猷.肝癌治疗的“消灭与改造并举”策略[J].实用肝脏病杂志,2015,18(2):113-114.
[4]中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-944.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:211-212.
[6]李牧婵,周易,夏清,等.原发性肝癌32例治疗用药规律分析[J].北京中医药,2017,36(8):732-735.
[7]张山雷.本草正义[M].福州:福建科学技术出版社,2006:16,44,229.
[8]常敏毅.日华子本草辑注[M].北京:中国医药科技出版社,2016:38.
[9]汪昂.本草备要[M].北京:中国中医药出版社,2008:53.
[10]倪朱谟.本草汇言[M].北京:中医古籍出版社,2005:18.
[11]兰茂.滇南本草[M].昆明:云南科技出版社,2004:282.
[12]田代华.黄帝内经素问[M].北京:人民卫生出版社,2005:47.
[13]李时珍.本草纲目[M].武汉:崇文书局,2017:171.
[14]甄权,尚志钧.药性论·药性趋向分类论[M].合肥:安徽科学技术出版社,2006:73.
[15]袁平凡.白芍总苷对二乙基亚硝胺诱导大鼠肝癌的作用及部分机制[D].合肥:安徽医科大学,2015.
[16]周剑,苏德春,宋国权.白术多糖对H22肝癌小鼠抗肿瘤作用的实验研究[J].亚太传统医药,2015,11(17):9-10.
[17]周曙,蔡涛,覃兴贵,等.黄芩苷诱导人肝癌Hep G2细胞凋亡的p38MAPK途径研究[J].临床军医杂志,2015,43(4):384-387.
[18]张彦兵,朱娇,肖菊香,等.白花蛇舌草总黄酮对TGF-B1诱导的肝癌MHCC97-H细胞EMT的逆转作用及其机制[J].西安交通大学学报(医学版),2016,37(2):279-282,306.
[19]徐吉敏,张世安,黄艳,等. MTT法研究酸枣仁皂苷A对肝细胞、肝星状细胞和肝癌细胞增殖的影像[J].西北药学杂志,2013,28(3):281-284.
[20]胡妮.枸杞多糖单用及联合CXCL10抗肝癌作用免疫机制研究[D].广州:广州中医药大学,2015.
[21]段华,王保奇,张跃文,等.黄精多糖对肝癌H22移植瘤小鼠的抑瘤作用及机制研究[J].中药新药与临床药理,2014,25(1):5-7.
[22]董继革,于洪侠.中医适宜技术在恶性肿瘤患者康复期的应用评价[J].中华肿瘤防治杂志,2018,25(S2):308-309.
[2]中华人民共和国卫生部.原发性肝癌诊疗规范2011年版[J].临床肿瘤学杂志,2011,16(10):929-946.
[3]汤钊猷.肝癌治疗的“消灭与改造并举”策略[J].实用肝脏病杂志,2015,18(2):113-114.
[4]中华人民共和国卫生部.原发性肝癌诊疗规范(2011年版)[J].临床肿瘤学杂志,2011,16(10):929-944.
[5]郑筱萸.中药新药临床研究指导原则(试行)[M].北京:中国医药科技出版社,2002:211-212.
[6]李牧婵,周易,夏清,等.原发性肝癌32例治疗用药规律分析[J].北京中医药,2017,36(8):732-735.
[7]张山雷.本草正义[M].福州:福建科学技术出版社,2006:16,44,229.
[8]常敏毅.日华子本草辑注[M].北京:中国医药科技出版社,2016:38.
[9]汪昂.本草备要[M].北京:中国中医药出版社,2008:53.
[10]倪朱谟.本草汇言[M].北京:中医古籍出版社,2005:18.
[11]兰茂.滇南本草[M].昆明:云南科技出版社,2004:282.
[12]田代华.黄帝内经素问[M].北京:人民卫生出版社,2005:47.
[13]李时珍.本草纲目[M].武汉:崇文书局,2017:171.
[14]甄权,尚志钧.药性论·药性趋向分类论[M].合肥:安徽科学技术出版社,2006:73.
[15]袁平凡.白芍总苷对二乙基亚硝胺诱导大鼠肝癌的作用及部分机制[D].合肥:安徽医科大学,2015.
[16]周剑,苏德春,宋国权.白术多糖对H22肝癌小鼠抗肿瘤作用的实验研究[J].亚太传统医药,2015,11(17):9-10.
[17]周曙,蔡涛,覃兴贵,等.黄芩苷诱导人肝癌Hep G2细胞凋亡的p38MAPK途径研究[J].临床军医杂志,2015,43(4):384-387.
[18]张彦兵,朱娇,肖菊香,等.白花蛇舌草总黄酮对TGF-B1诱导的肝癌MHCC97-H细胞EMT的逆转作用及其机制[J].西安交通大学学报(医学版),2016,37(2):279-282,306.
[19]徐吉敏,张世安,黄艳,等. MTT法研究酸枣仁皂苷A对肝细胞、肝星状细胞和肝癌细胞增殖的影像[J].西北药学杂志,2013,28(3):281-284.
[20]胡妮.枸杞多糖单用及联合CXCL10抗肝癌作用免疫机制研究[D].广州:广州中医药大学,2015.
[21]段华,王保奇,张跃文,等.黄精多糖对肝癌H22移植瘤小鼠的抑瘤作用及机制研究[J].中药新药与临床药理,2014,25(1):5-7.
[22]董继革,于洪侠.中医适宜技术在恶性肿瘤患者康复期的应用评价[J].中华肿瘤防治杂志,2018,25(S2):308-309.